Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06147882
Other study ID # duzceuniversityhamide001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date May 20, 2024
Est. completion date May 21, 2024

Study information

Verified date March 2024
Source Duzce University
Contact Hamide Erol
Phone 05064764068
Email hamideerol01@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fibromyalgia (FM) is characterized by symptoms such as chronic widespread pain, severe fatigue, sleep disturbances, extremity paresthesia, stiffness, mood disturbances, and cognitive impairment lasting more than 3 months without an alternative explanation. Although the exact etiology and pathogenesis of FM is still unknown, it has been suggested that stress or psychological factors may play a key role in the syndrome. 1,2,3 Positive Psychotherapy supports individuals in symptom management to use their resources to overcome difficulties, understand and recognize growth areas with a therapeutic approach.4 In this respect, it overlaps with the professional purpose of mental health and psychiatric nursing (RSPH). The aim of this study; In this study, it is aimed to report the process of examining the pain perception, daily life activities and mental health of patients with fibromyalgia syndrome (FMS) and the effectiveness of the psychoeducation program based on Positive Psychotherapy (PPT).


Description:

The research is planned to be carried out between June 2023 and June 2024. The study will be conducted with patients diagnosed with FMS, who applied to a private Medical Center Orthopedics Outpatient Clinic in Düzce. The research was planned as a randomized controlled trial. The sample of the study will consist of patients selected by the randomization selection method who meet the inclusion criteria. The Gpower 3.1 program was used to determine the number of patients in the experimental and control groups of the study. In this context, two-way analysis of variance (TWO-WAY-ANOVA) method will be used. In conditions where the effect level was 0.40 (large effect), the error level (a) was 0.05, and the power of the test (1-B) was 0.95, the minimum sample size required for a statistically significant difference between the groups and between the measurements was obtained as 58. Each group must have at least 29 participants. In studies on the dependent variable in the literature, the drop out rate was found to be 6-12 (10-12%). Therefore, in this study, the drop out rate will be taken as 10, and the sample size will be determined as 34 for each group. The study was planned as 3 stages as randomized controlled pre-test, repeated post-test and 3rd month follow-up test. Within the scope of the study, Introductory Information Form, Visual Analogue Scale (VAS) (will be measured 3 times), Fibromyalgia Impact Questionnaire (FIQ) (will be measured 3 times), General Health Questionnaire-28 (GSA-28) (will be measured 3 times) will be applied. Within the scope of the research, it was planned to apply a PPT-based Psychoeducation Program consisting of 10 sessions, each of 120-90 minutes, to a group of participants diagnosed with FMS. The program to be implemented within the scope of the research was prepared after the literature review and together with the participant's handbook, it was sent to Positive Psychotherapy experts to get expert opinions. After the expert evaluations, necessary arrangements were made and the program was finalized. The applied Positive Psychotherapy group program was developed by the researcher by scanning the literature, the session contents, which blend three basic principles, including the real abilities of PPT, the balance model and the five-step therapy process, in order to minimize the symptoms that limit the daily life activities of FMS patients and create problems in their social lives. Information to be given, practices to be given and homework to be given for each session were determined. The purpose of the sessions was prepared by determining the targets expected to be achieved by the participants at the end of each session.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 72
Est. completion date May 21, 2024
Est. primary completion date May 21, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Being between the ages of 18-65, - Having been diagnosed with Fibromyalgia Syndrome according to the 2016 ACR diagnostic criteria for at least 1 year, - Agreeing to participate in the study. Exclusion Criteria: Those in acute depression - History of a recent cardiac event such as myocardial infarction, - History of significant head trauma, - Peripheral neuropathy, - Use of some centrally acting analgesic drugs such as opioids, - History of substance and alcohol abuse, - Concomitant autoimmune or inflammatory disease, - Diseases affecting the central nervous system (for example, multiple sclerosis, Parkinson's disease), - Serious psychiatric conditions that prevent participation (for example, psychotic disorders). - Previously, therapy, counseling, personal development, etc. to have received

Study Design


Intervention

Behavioral:
The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.
The group will include patients with fibromyalgia syndrome who will receive positive psychotherapy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Duzce University

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Pain Perception of Fibromyalgia Syndrome Patients from Baseline Pain will be used to evaluate by VAS (Visual Anolog Scale) Line: A horizontal line is usually used, with the left end representing one extreme (e.g., "no pain" or "not at all") and the right end representing the other extreme (e.g., "worst pain imaginable" or "extremely intense").
Length: The line is typically 100 millimeters long Participants are provided with instructions explaining what the scale measures (e.g., pain intensity) and are asked to mark a point on the line that best represents their experience.
Scoring: Measurement is done by measuring the distance in millimeters from the left end of the line to the point marked by the participant. This provides a numerical score that quantifies the individual's perception.
Interpretation: A higher score on the VAS generally indicates a more intense or severe experience of the measured phenomenon.
Pre-test (Before positive psychotherapy group intervention), Post- test (10 weeks after therapy) and Follow up (12 weeks after therapy)
Primary Change in daily living activities of fibromyalgia patients from baseline Fibromyalgia Impact Questionnaire The Fibromyalgia Impact Questionnaire (FIQ) is a self-administered questionnaire designed to assess the health status and impact of fibromyalgia on individuals. It was developed to provide a comprehensive overview of the various aspects of fibromyalgia, including physical functioning, symptoms, and overall well-being.
Physical Functioning:
Work Status:
Questions address how fibromyalgia affects an individual's ability to work.
Depression and Anxiety:
The FIQ includes questions about emotional well-being, assessing symptoms of depression and anxiety.
Morning Tiredness:
Measures the level of fatigue and tiredness experienced in the morning, providing insights into the impact of fibromyalgia on sleep and morning functioning.
Pain Levels:
Questions related to the intensity of pain experienced by individuals with fibromyalgia.
Stiffness:
Assesses the extent of stiffness experienced by individuals, which is a common symptom of fibromyalgia.
Pre-test (Before positive psychotherapy group intervention), Post- test (10 weeks after therapy) and Follow up (12 weeks after therapy)
Secondary Change in the mental health of fibromyalgia patients from the beginning General Health Questionnaire-28 General Health Questionnaire -28 is a self-filled screening test designed to detect mental health problems encountered in society and non-psychiatric clinical settings. The survey consists of four subsections, each consisting of seven items. These sections; Somatic symptoms include anxiety and sleep disorders, impairment in social functioning, and major depression. The 28-item scale consists of a question about whether each individual has a recent complaint and a four-item response ranging from "less than usual" to "much more than usual". After the application, a minimum score of 0 and a maximum of 28 points can be obtained, and a higher score increases the likelihood of mental health disorders. Pre-test (Before positive psychotherapy group intervention), Post- test (10 weeks after therapy) and Follow up (12 weeks after therapy)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05933486 - Efficacy and Safety of Tongluo-Kaibi Tablet in Patients With Fibromyalgia Syndrome Phase 4
Completed NCT01642810 - Online Acceptance-based Behavioural Treatment for Fibromyalgia Phase 3
Completed NCT00757731 - FMS European Long-Term Study Phase 3
Completed NCT00757679 - Evaluation of the Antinociceptive and Analgesic Effects of Milnacipran Phase 2
Completed NCT01968772 - Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia N/A
Completed NCT00401830 - Assessing Efficacy and Safety of Lacosamide Compared to Placebo in Reducing Signs and Symptoms of Fibromyalgia Syndrome. Phase 2
Completed NCT04517929 - Effectiveness of Group Psychotherapy in Patients With Fibromyalgia Syndrome N/A
Completed NCT06285045 - Study on Roujin Formula in the Treatment of Fibromyalgia Syndrome With Blood Deficiency and Liver Depression N/A
Active, not recruiting NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2
Completed NCT02800720 - Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome N/A
Not yet recruiting NCT01465477 - Influenza Vaccination in Fibromyalgia Patients N/A
Completed NCT00528710 - Efficacy of S-Adenosylmethionine in Fibromyalgia Phase 2
Completed NCT00447083 - Benefits of Tanning in Fibromyalgia Patients N/A
Completed NCT05381012 - Fibromyalgia Syndrome on Patients With Chronic Migraine N/A
Completed NCT00464737 - The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults. Phase 2
Completed NCT04426864 - Efficacy of Different Types of Exercises in Women With Fibromyalgia Syndrome. N/A
Completed NCT02881411 - Self Soft Tissue Therapy for Fibromyalgia Syndrome N/A
Completed NCT01389336 - Add-on Complex Ayurvedic Treatment in Fibromyalgia-Syndrome Compared to Standard Care Alone N/A
Not yet recruiting NCT01147263 - Palpitations and Tachycardia in Fibromyalgia Syndrome N/A
Completed NCT00222274 - HRV Biofeedback in Fibromyalgia N/A